# US 2002/0058260 A1 · Method for identifying microbial proliferation genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058260 A1
- Document ID: US20020058260A1
- Status: Published application
- Kind: A1
- Application number: 09/805,664
- Filed: 2001-03-13
- Published: 2002-05-16
- Earliest claimed: 1997-11-14
- Assignees: San Diego State University Foundation, California corporation
- Inventors: Judith W. Zyskind; R. Allyn Forsyth
- Web page: https://patentgrep.com/patent/US20020058260A1

## CPC

- C12N 15/1072: {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- C12N 15/1079: {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086)}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for identifying endogenous microbial proliferation genes for growth and viability is disclosed herein. The method involves exogenous nucleic acids that are used to conditionally produce antisense inhibitors of endogenous complementary mRNAs in a microorganism. Antisense fragments that result in lethality when expressed indicate that the endogenous gene is a proliferation gene. The method can also be used with sequences in sense orientation. The strategy can be used to identify new gene targets for novel antibiotics.

## Claims

### Claim 1

A method of screening for an antimicrobial agent, comprising the steps of:
(a) providing a test compound, a microbial proliferation gene and a first and a second sample of a microorganism,
wherein the microbial proliferation gene is identified by introducing an exogenous nucleic acid into the microorganism, the exogenous nucleic acid having substantial sequence identity to an endogenous microbial gene, wherein the exogenous nucleic acid is a random fragment or a random sequence, and, identifying the endogenous gene as a microbial proliferation gene by comparing the proliferation or viability of the microorganism when the exogenous nucleic acid is expressed in or introduced into the microorganism with the proliferation or viability of the microorganism when the exogenous nucleic acid is not present or not expressed,
(b) introducing the microbial proliferation gene into the microorganism of the first sample;
(c) contacting the test compound with the first sample and the second microorganism samples; and
(d) determining the effect of the test compound on the first and the second microorganism samples, wherein the test compound is identified as an antimicrobial agent by comparing the effect of contacting the test compound to the first sample, where the exogenous nucleic acid is expressed or introduced, to the effect of contacting the test compound to the second sample, where the exogenous nucleic acid is not present, and the effect of the test compound on the contacted microorganism differs between the first and the second samples, thereby identifying the test compound as an antimicrobial agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a change in the rate of proliferation of the contacted first microorganism sample as compared to the contacted second microorganism sample, thereby identifying the test compound as an anti-proliferative antimicrobial agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a microbiostatic effect on the contacted first microorganism sample as compared to the contacted second microorganism sample, thereby identifying the test compound as a microbiostatic antimicrobial agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a microbiocidal effect on the contacted first microorganism as compared to the contacted second microorganism sample, thereby identifying the test compound as a microbiocidal antimicrobial agent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the first microorganism sample as compared to the second microorganism sample is a change in the rate of transcription or amount of a transcription product of the microbial proliferation gene in the first microorganism sample.

### Claim 6 (depends on 5)

The method of claim 5, wherein the transcription product is an RNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the transcription product is an mRNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effect of contacting the antimicrobial agent with the microorganism is a change in the rate of translation or amount of a translation product of the microbial proliferation gene.

### Claim 9 (depends on 8)

The method of claim 8, wherein the translation product is a polypeptide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a change in the activity of a translation product of the microbial proliferation gene.

### Claim 11 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a change in metabolism of the contacted microorganism.

### Claim 12 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a change in viability of the contacted microorganism.

### Claim 13 (depends on 1)

The method of claim 1, wherein an effect of the test compound is determined indirectly.

### Claim 14 (depends on 13)

The method of claim 13, wherein an effect of the test compound is determined by a protein activity assay.

### Claim 15 (depends on 14)

The method of claim 14, wherein the effect of the test compound agent is determined by an enzyme assay.

### Claim 16 (depends on 13)

The method of claim 13, wherein the effect of the test compound is determined by an immunoassay.

### Claim 17 (depends on 1)

The method of claim 1, wherein the effect of contacting the test compound with the microorganism is a change in the rate of proliferation, metabolism or viability of the contacted first microorganism sample as compared to the contacted second microorganism sample, thereby identifying the test compound as an antibiotic.

### Claim 18 (depends on 1)

The method of claim 1, wherein introducing the microbial proliferation gene into the microorganism of the first sample results in an increased level of expression of the transcription or translation product of the gene, thereby requiring contacting more test compound to the first sample than to the second sample to have the same effect on the microorganism.

### Claim 19 (depends on 1)

The method of claim 1, wherein introducing the microbial proliferation gene into the microorganism of the first sample results in an decreased level of expression or activity of the translation product of an endogenous microbial proliferation gene, thereby requiring contacting less test compound to the first sample than to the second sample to have the same effect on the microorganism.

### Claim 20 (depends on 19)

The method of claim 19, wherein the microbial proliferation gene is operably linked to a transcriptional regulatory element effective for controlling expression of the exogenous nucleic acid.

### Claim 21 (depends on 20)

The method of claim 20, wherein the transcriptional regulatory element effective for controlling expression of the microbial proliferation gene is an inducible regulatory sequence.

### Claim 22 (depends on 21)

The method of claim 21, wherein the inducible regulatory sequence that controls expression of the microbial proliferation gene is a promoter induced in response to a chemical inducer.

### Claim 23 (depends on 22)

The method of claim 22, wherein chemical inducer comprises isopropyl-beta-D-thiogalactopyranoside, tetracycline or tryptophan.

### Claim 24 (depends on 21)

The method of claim 21, wherein the inducible regulatory sequence that controls expression of the microbial proliferation gene is a promoter induced in response to environmental changes.

### Claim 25 (depends on 20)

The method of claim 20, wherein the microbial proliferation gene is operably linked in an antisense orientation to the transcriptional regulatory element.

### Claim 26 (depends on 20)

The method of claim 20, wherein the microbial proliferation gene is operably linked in a sense orientation to the transcriptional regulatory element.

### Claim 27 (depends on 1)

The method of claim 1, wherein introducing the microbial proliferation gene into the microorganism of the first sample results in an decreased level of expression of the transcription product of an endogenous microbial proliferation gene, thereby requiring contacting less test compound to the first sample than to the second sample to have the same effect on the microorganism.

### Claim 28 (depends on 27)

The method of claim 27, wherein the microbial proliferation gene is operably linked to a transcriptional regulatory element effective for controlling expression of the exogenous nucleic acid.

### Claim 29 (depends on 28)

The method of claim 28, wherein the transcriptional regulatory element effective for controlling expression of the microbial proliferation gene is an inducible regulatory sequence.

### Claim 30 (depends on 29)

The method of claim 29, wherein the inducible regulatory sequence that controls expression of the microbial proliferation gene is a promoter induced in response to a chemical inducer.

### Claim 31 (depends on 30)

The method of claim 30, wherein chemical inducer comprises isopropyl-beta-D-thiogalactopyranoside, tetracycline or tryptophan.

### Claim 32 (depends on 29)

The method of claim 29, wherein the inducible regulatory sequence that controls expression of the microbial proliferation gene is a promoter induced in response to environmental changes.

### Claim 33 (depends on 28)

The method of claim 28, wherein the microbial proliferation gene is operably linked in an antisense orientation to the transcriptional regulatory element.

### Claim 34 (depends on 28)

The method of claim 28, wherein the microbial proliferation gene is operably linked in a sense orientation to the transcriptional regulatory element.

### Claim 35 (depends on 1)

The method of claim 1, wherein the microbial proliferation gene is endogenous to the microorganism.

### Claim 36 (depends on 1)

The method of claim 1, wherein the microbial proliferation gene is a bacterial proliferation gene.

### Claim 37 (depends on 36)

The method of claim 36, wherein the bacterial proliferation gene has substantial sequence identity to the E. coli viaA gene.

### Claim 38 (depends on 36)

The method of claim 36, wherein the bacterial proliferation gene has substantial sequence identity to the E. coli orf1 gene.

### Claim 39 (depends on 36)

The method of claim 36, wherein the bacterial proliferation gene has substantial sequence identity to the E. coli lepB gene.

### Claim 40 (depends on 36)

The method of claim 36, wherein the bacterial gene has substantial sequence identity to the E. coli ugpB gene.

### Claim 41 (depends on 36)

The method of claim 36, wherein the bacterial proliferation gene has substantial sequence identity to the E. coli ddlB gene.

### Claim 42 (depends on 36)

The method of claim 36, wherein the bacterial proliferation gene has substantial sequence identity to the E. coli secA gene.

### Claim 43 (depends on 36)

The method of claim 36, wherein the bacterial proliferation gene has substantial sequence identity to a gene having sequence identity to E. coli fimF or fimD.

### Claim 44 (depends on 1)

The method of claim 1, wherein the microorganism is a pathogen.

### Claim 45 (depends on 1)

The method of claim 1, wherein the microorganism is a bacterium.

### Claim 46 (depends on 45)

The method of claim 45, wherein the bacterium is a pathogen.

### Claim 47 (depends on 45)

The method of claim 45, wherein the bacterium is a gram-negative bacterium.

### Claim 48 (depends on 47)

The method of claim 47, wherein the gram-negative bacterium is Escherichia coli.

### Claim 49 (depends on 47)

The method of claim 47, wherein the bacterium is a gram-positive bacterium.

### Claim 50 (depends on 49)

The method of claim 49, wherein the gram-positive bacterium is Staphylococcus aureus.

### Claim 51 (depends on 1)

The method of claim 1, wherein the microorganism is a fungus.

### Claim 52 (depends on 1)

The method of claim 1, wherein the microorganism is a yeast.

### Claim 53 (depends on 1)

The method of claim 1, wherein the microorganism is an Archaebacteria.

### Claim 54 (depends on 44)

The method of claim 44, wherein the microorganism is a human pathogen.

### Claim 55 (depends on 44)

The method of claim 44, wherein the microorganism is an animal pathogen.

### Claim 56 (depends on 44)

The method of claim 44, wherein the microorganism is a plant pathogen.

### Claim 57 (depends on 1)

The method of claim 1, wherein the exogenous nucleic acid is operably linked to a transcriptional regulatory element effective for controlling expression of the exogenous nucleic acid.

### Claim 58 (depends on 57)

The method of claim 57, wherein the transcriptional regulatory element effective for controlling expression of the exogenous nucleic acid is an inducible regulatory sequence.

### Claim 59 (depends on 58)

The method of claim 58, wherein the inducible regulatory sequence that controls expression of the exogenous nucleic acid is a promoter induced in response to a chemical inducer.

### Claim 60 (depends on 59)

The method of claim 59, wherein chemical inducer comprises isopropyl-beta-D-thiogalactopyranoside, tetracycline or tryptophan.

### Claim 61 (depends on 58)

The method of claim 58, wherein the inducible regulatory sequence that controls expression of the exogenous nucleic acid is a promoter induced in response to environmental changes.

### Claim 62 (depends on 57)

The method of claim 57, wherein the exogenous nucleic acid is operably linked in an antisense orientation to the transcriptional regulatory element.

### Claim 63 (depends on 57)

The method of claim 57, wherein the exogenous nucleic acid is operably linked in a sense orientation to the transcriptional regulatory element.

### Claim 64 (depends on 1)

The method of claim 1, wherein the exogenous nucleic acid further comprises a vector.

### Claim 65 (depends on 64)

The method of claim 64, wherein the vector is a plasmid or a phage vector.

### Claim 66 (depends on 1)

The method of claim 1, wherein the exogenous nucleic acid is from about to about 5,000 nucleotides in length.

### Claim 67 (depends on 66)

The method of claim 66, wherein the exogenous nucleic acid is from about to about 1,500 nucleotides in length.

### Claim 68 (depends on 1)

The method of claim 1, wherein the exogenous nucleic acid is obtained from a nucleic acid selected from the group consisting of chromosomal DNA, episomal genomic DNA, RNA, cDNA and synthetic DNA.

### Claim 69 (depends on 1)

The method of claim 1, wherein the test compound comprises a combinatorial library.

### Claim 70 (depends on 1)

The method of claim 1, wherein the test compound comprises an inorganic compound.

### Claim 71 (depends on 1)

The method of claim 1, wherein the test compound comprises an organic compound.

### Claim 72 (depends on 1)

The method of claim 1, wherein the test compound comprises a peptidomimetic.

### Claim 73 (depends on 1)

The method of claim 1, wherein the test compound comprises a polypeptide or a peptide.

### Claim 74 (depends on 1)

The method of claim 1, wherein the test compound comprises an oligonucleotide or a polynucleotide.

### Claim 75 (depends on 1)

The method of claim 1, wherein determining the effect of the test compound on the microorganism comprises comparative or replica plating of the microorganism.

### Claim 76 (depends on 1)

The method of claim 1, wherein determining the effect of the test compound on the microorganism comprises measuring respiratory activity.

### Claim 77 (depends on 1)

The method of claim 1, wherein determining the effect of the test compound on the microorganism comprises measuring colony-forming units, light scattering or optical density, the number of organisms in a particle counter, the fluorescence of cell cultures or of individual cells after addition of fluorescent dyes, the incorporation of precursors to macromolecules or the uptake of metabolites.

### Claim 78 (depends on 1)

The method of claim 1, wherein the microorganism is a viable cell.

### Claim 79 (depends on 1)

The method of claim 1, wherein the microorganism is a crude cell lysate.

### Claim 80 (depends on 1)

The method of claim 1, wherein the test compound targets a transcription product of the microbial proliferation gene.

### Claim 81 (depends on 80)

The method of claim 80, wherein the transcription product is an RNA.

### Claim 82 (depends on 81)

The method of claim 81, wherein the transcription product is an mRNA.

### Claim 83 (depends on 80)

The method of claim 80, wherein the test compound selectively binds to the transcription product.

### Claim 84 (depends on 1)

The method of claim 1, wherein the test compound targets a translation product of the microbial proliferation gene.

### Claim 85 (depends on 84)

The method of claim 84, wherein the translation product is a polypeptide.

### Claim 86 (depends on 84)

The method of claim 84, wherein the test compound selectively binds to the translation product.

### Claim 87

A method of screening for antibacterial agents, comprising the steps of:
(a) providing a test compound, a microbial proliferation gene and a first and a second sample of a bacterium,
wherein the bacterial proliferation gene is identified by introducing an exogenous nucleic acid into the bacterium, the exogenous nucleic acid having substantial sequence identity to an endogenous bacterial gene, wherein the exogenous nucleic acid is a random fragment or a random sequence, and, identifying the endogenous gene as a bacterial proliferation gene by comparing the proliferation or viability of the bacterium when the exogenous nucleic acid is expressed in or introduced into the bacterium with the proliferation or viability of the bacterium when the exogenous nucleic acid is not present or not expressed,
(b) introducing the bacterial proliferation gene into the bacterium of the first sample;
(c) contacting the test compound with the first sample and the second bacterium samples; and
(d) determining the effect of the test compound on the first and the second bacterial samples, wherein the test compound is identified as an anti-proliferative anti-bacterial agent by comparing the effect of contacting the test compound to the first sample, where the exogenous nucleic acid is expressed or introduced, to the effect of contacting the test compound to the second sample, where the exogenous nucleic acid is not present, and the effect of the test compound on the contacted bacterium differs between the first and the second samples, thereby identifying the test compound as an anti-bacterial agent.

### Claim 88

A cell system for identifying an antimicrobial agent, comprising a microbial proliferation gene, a first and a second sample of a microorganism, and instructions for
(a) identifying the microbial proliferation gene by introducing an exogenous nucleic acid into the microorganism, the exogenous nucleic acid having substantial sequence identity to an endogenous microbial gene, wherein the exogenous nucleic acid is a random fragment or a random sequence, and, identifying the endogenous gene as a microbial proliferation gene by comparing the proliferation or viability of the microorganism when the exogenous nucleic acid is expressed in or introduced into the microorganism with the proliferation or viability of the microorganism when the exogenous nucleic acid is not present or not expressed,
(b) introducing the microbial proliferation gene into the microorganism of the first sample;
(c) contacting a test compound with the first sample and the second microorganism samples; and
(d) determining the effect of the test compound on the first and the second microorganism samples, wherein the test compound is identified as an antimicrobial agent by comparing the effect of contacting the test compound to the first sample, where the exogenous nucleic acid is expressed or introduced, to the effect of contacting the test compound to the second sample, where the exogenous nucleic acid is not present, and the effect of the test compound on the contacted microorganism differs between the first and the second samples, thereby identifying the test compound as an antimicrobial agent.
